Survey: Opinions on the Studies Outlined Within ICH S7 Guidance
Krystle G. Correll
Survey into opinions on the studies outlined within ICH S7 guidance
The ICH S7 guidance describes nonclinical safety pharmacology studies as core battery, follow-up or additional studies. The availability of new and evolving technologies, as well as a wish to streamline packages and animal use, has led to many organizations successfully implementing fit-for-purpose testing approaches (for small molecules, biologics and new modalities) which complement the established studies outlined within ICHS7A/B.
In order to ascertain how the guidance is used and the relevance of individual studies to current drug development portfolios, the Safety Pharmacology Society and NC3Rs have generated a short survey to gather high-level information on the opinions of individual scientists into the scope for revisiting the guidance.
The survey will be open until August 30, and the results of the survey will be presented during the Revisiting ICH S7A and S7B Session at the Safety Pharmacology Society meeting on Thursday, September 26, 2019 in Barcelona, Spain.
If you design or run safety pharmacology studies, or use the data to make decisions on drug safety, please take a few moments to complete the survey. It should take less than 10 minutes to complete the survey.
During our 2020 Virtual Annual Meeting, September 14-17, 2020, the Safety Pharmacology Society recognized the award recipients for our Translational Safety Pharmacology Publication Award and Technolog...